Stephen Marley Launches Plant-Based CBD Personal Care Line

Dec.14.2022
Stephen Marley Launches Plant-Based CBD Personal Care Line
Stephen Marley releases plant-based Kx Family Care, featuring CBD-infused Hair and Beard Oil, Pain Relief Balm, and more.

On Monday, Grammy-winning artist Stephen Marley launched a product line called Kx Family Care, which is a plant-based CBD personal care collection that utilizes the benefits of cannabis and other herbs traditionally used in Jamaica.


The debut series features limited holiday packages containing two products: a versatile hair and beard oil, and a pain relief balm both infused with full spectrum CBD oil, known for its anti-inflammatory, antibacterial, and antioxidant properties.


These two products also contain sunflower oil, vitamin E, and linoleic acid, which have antioxidants that help protect the skin from free radical damage and maintain its natural barrier. They also contain black seed oil, sapodilla fruit extracts, and star apple, which are widely used in Jamaican culture for their regenerative properties.


For example, Jamaican black castor oil comes from the seeds of the Nigella sativa plant, which is rich in antioxidants and offers various health benefits.


Kx Family Care is a natural progression for me, due to my passion for the cannabis plant and its various uses," said founder Stephen Marley. "This brand is authentic in every way, from the natural infusion of Jamaican plants in our products, to the eco-friendly wood and glass packaging we use. Our goal is centered on family, natural health, sustainability, and respect for the many uses of the cannabis plant.


Kx Family Care is the multi-generational personal-care product branch of Kaya Lifestyle, owned and operated by Marley. Kaya Lifestyle also hosts Kaya Fest, a music and education cannabis advocacy festival.


Marley joined the CEO and co-founder Shelly O'Neill to spend three years researching and developing a plant-based, multipurpose product designed specifically for busy families. Marley believes that marijuana is just like any other useful herb. "Marijuana is an herb, like mint or sage, that can cure many diseases and provide spiritual enlightenment," Marley told the cultural magazine in 2018.


The idea for Kx Family Care arose while O'Neill and Marley were working together at Kaya Fest, a world music festival organized by Marley to promote education surrounding the various uses of the cannabis plant. The term "Kaya" is a Jamaican slang word for herb, derived from the Caribbean English word "kayakiit," meaning a type of herb.


Experience Marley's cannabis products firsthand: Kx Family Care's pop-up store will be opening on specific dates during Stephen Marley's upcoming Old Soul Tour - Unplugged 2023.


We are pleased to introduce the first all-natural, cannabis-based personal care brand that is safe and effective for the entire family," said founder Stephen Marley. "We look forward to giving our customers a firsthand experience of the Kx Family Care pop-up store at the specific date of The Old Soul Tour - Unplugged in 2023.


The company stated that the US Food and Drug Administration (FDA) does not require basic safety testing on ingredients in personal care products. These products often contain toxic ingredients that can harm the skin and hair.


The company also maintains its commitment to the environment in its packaging.


Kx Family Care aims to utilize eco-friendly materials including hemp plastic to showcase the various uses of the cannabis plant and reduce plastic waste, according to its website. Inspired by Jamaica's nickname as the "land of wood and water," the company captures the essence by using biodegradable wood and glass in its packaging. Kx also spreads love by supporting different charitable organizations every quarter with a portion of its sales revenue.


Several siblings and family members of Marley have ventured into the CBD or cannabis business, including Ziggy and Damian.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23